Genomic complexity and AKT dependence in serous ovarian cancer.
about
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapyTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyCombination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifierHiding in the dark: uncovering cancer drivers through image-guided genomics.Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.An integrated network of microRNA and gene expression in ovarian cancer.Oncolytic virotherapy for ovarian cancer.PTN signaling: Components and mechanistic insights in human ovarian cancer.A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput formatAKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axisOvarian cancer: emerging molecular-targeted therapies.The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell linesPrevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.New developments in the treatment of ovarian cancer--future perspectives.Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases.Amplification of USP13 drives ovarian cancer metabolism.In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.Akt isoform specific effects in ovarian cancer progression.Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.The role of biomarkers in the management of epithelial ovarian cancer.Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms.KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.Preferential effect of akt2-dependent signaling on the cellular viability of ovarian cancer cells in response to EGF.ABT-737 and pictilisib synergistically enhance pitavastatin-induced apoptosis in ovarian cancer cells.Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.Deptor is a novel target of Wnt/β-catenin/c-Myc and contributes to colorectal cancer cell growth.Bayesian graphical models for computational network biology.
P2860
Q50432263-5E5C6A32-7360-41EA-B4AC-7A5B1B4BB280Q54606559-557D903D-2EBD-4999-B3FA-F37B9B730D23Q54796229-4B674291-5EBE-417B-B4C6-E781056A3DE7Q54808585-16A865E7-9C7C-41F9-B7C7-930F1F0AB557Q54832435-CE0211CD-3286-4ACD-8FAC-61357A4FFEFDQ54897382-F40C4830-FEAA-4FAA-9D68-0A891BE048ECQ54904669-684D52D3-095D-4F90-A63B-7B5F3AA5E483Q54936822-1CAAD935-9125-4020-852C-593AC6434A0AQ54936833-6D643008-F4CD-47C6-B806-15EBEBD7F792Q54936989-48F1F782-6F89-4DE6-A898-E93C1056B2B5Q54937005-B081727C-B406-4B81-AE66-A449649B137DQ54937011-057D2B02-CAE1-4990-87BF-AC48453BCE72Q54947162-B592AA5C-169E-4157-97F5-7866E32C6DA3Q54947168-3903E4D0-9E5C-481B-ABD0-5038565D6CE5Q54954504-5B1BD3F8-A2FF-4176-A1CE-F19F98688ABBQ54954507-2C9CB31B-8565-44B5-B917-5101153DFD10Q54972795-AD3F8FA5-98D7-4FCE-97A6-9E1AC2B74D80
P1343
Q27852894-0653E8AF-7266-411B-A61B-92953E4555F9Q28285473-8EBA3DE8-4B54-4922-A318-C9C8FED25E9EQ28550300-EF288553-018C-4644-8109-AB5EDC99D9BBQ34001762-71772A82-AF6F-4B6F-81D0-D7A1FA6660F9Q34074997-EE62CB33-5288-4E8D-BFA6-3AFB7E1E51B2Q34096767-7920F58B-E1A0-4CEC-A577-3DE9E4336CF8Q34717933-EC5EC234-57E9-4DF4-B263-E86112087742Q34720998-A415DF78-CCC1-40F1-B75A-3D993CE98E17Q35030274-5899FC0E-1C95-4D86-B933-A7D0BF16F348Q35237915-B20FEC08-915A-4127-9D14-96A4399092C3Q35477129-A0BB541D-9F16-4CBE-B93D-B57226B9430DQ35597082-7CB011BC-4111-49FC-B65A-893C404E8EFCQ35685365-60CD0185-70FA-46E2-BE36-7535409794E2Q35817502-7433A774-3B15-43BF-B72F-387FE9AEC06AQ35987253-65BBF851-2BDF-4394-80C6-40254B77415EQ36092472-9ED9DD32-D66B-4774-89E3-623B5526E005Q36413227-2FAF72FA-E09D-44C9-9EAB-6A5D7BE8B596Q37122307-133308E7-9924-4227-A6B0-142FEFCE04FEQ37155964-F66C41FC-23B1-4DFC-9C36-64AA5310265CQ37332487-D0B6D73F-A6E7-4C56-9529-96A8DFDD80BFQ37417687-B8C5219B-8969-40A0-B031-D20E6F3BD700Q37465116-F26F2F3F-489D-443A-A60A-785C74BE4C36Q37519684-1D520485-F27B-4B7D-A05A-94DF1B651656Q37684642-7854A26A-F983-4F99-9CDD-C3198C794BF5Q37688855-35ACAD7B-6B8B-4F9A-A903-DA84E92FBD5BQ37708115-A2C074A8-EBBE-4356-9981-C8A230ED564FQ38236320-211A259E-750D-4E78-8719-F6EC429F185BQ38532510-9DBF547A-685B-4E47-9F47-82BF39C4EA76Q38962245-28428BE4-E566-4FFB-BA10-6CC07C4F5A1AQ39208340-DFA78C90-405E-4BF8-887D-AC17BBFFC889Q39281140-7C31A342-31D8-4413-A28E-534200881561Q39411958-39B009F2-34B8-40CB-B192-690D72D538D6Q41949668-8BE53AD1-E21A-4A3A-808A-61122A1A4E87Q42382162-44ACDF55-0A7F-4482-824D-7E28D4215BB5Q42774672-DC47994B-3C02-4FD3-B607-195F7B2EBD34Q42914388-7B881574-B909-46F9-8497-87863BFCCF0BQ50041754-568275E7-F05F-4090-8206-DC1F42632865Q50932992-DDA56D23-C255-4D6C-BC28-BD695F790E49Q52582285-5062E400-F321-4FDE-AD3C-71BBB9BF875DQ52626051-2A35ABCD-DECC-4D4A-AAFC-24950C20182E
P2860
Genomic complexity and AKT dependence in serous ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Genomic complexity and AKT dependence in serous ovarian cancer.
@ast
Genomic complexity and AKT dependence in serous ovarian cancer.
@en
type
label
Genomic complexity and AKT dependence in serous ovarian cancer.
@ast
Genomic complexity and AKT dependence in serous ovarian cancer.
@en
prefLabel
Genomic complexity and AKT dependence in serous ovarian cancer.
@ast
Genomic complexity and AKT dependence in serous ovarian cancer.
@en
P2093
P2860
P4510
P50
P1433
P1476
Genomic complexity and AKT dependence in serous ovarian cancer.
@en
P2093
Adriana Heguy
Aphrothiti J Hanrahan
Barry S Taylor
Carol Aghajanian
Chris Sander
David B Solit
David R Spriggs
Dilip D Giri
Douglas A Levine
Ellen V Stevens
P2860
P356
10.1158/2159-8290.CD-11-0170
P577
2012-01-01T00:00:00Z